Brief: Novakand Pharma Evaluates Options After Decision Not To Execute Reverse Take Over
25/02/2026 15:48
Feb 25 (Reuters) - Novakand Pharma AB NOVKAN.ST: BOARD EVALUATES OPTIONS AFTER DECISION NOT TO EXECUTE PLANNED REVERSE TAKE OVER OF SVF VACCINES OPTIONS INCLUDE DE-LISTING, VOLUNTARY LIQUIDATION, RE-LISTING ON ANOTHER STOCK EXCHANGE Source text: ID:nMFN2FqHny Further company coverage: NOVKAN.ST (Gdansk Newsroom) ((gdansk.newsroom@thomsonreuters.com; +48 58 7696600;))
Recent news on Novakand Pharma AB
See all newsBrief: Nasdaq Decides To Delist Novakand From First North Growth Market
Brief: Novakand Pharma Extends Peter Selin's CEO Employment
Brief: Novakand Board Proposes New Business Direction, Relisting
Brief: Novakand Pharma Evaluates Options After Decision Not To Execute Reverse Take Over
Brief: Nasdaq Rejects Novakand's Application For Continued Listing